NorthWest Biotherapeutics Inc (NWBO)

[eagle8]

d_stock
@d_stock07734
$NWBO

April marks the primary completion of a DC1 vaccine trial (NCT05378464) conducted at Moffitt Cancer Center. The trial is about the following combination:

DC1 vaccine + Pepinemab(SEMA4D inhibitor) + Trastuzumab (HER2 inhibitor) + IL-15 Expanded HER2 specific CD4 Th1 cell + IL-7 Expanded HER2 specific CD4 Th1 cell

It is interesting IL-7 was used to expand HER2 CD4 Th1 cell. Is IL-7 about CYT107?

I suppose the results should be blockbuster given that the combination of DC1 vaccine with Pepinemab(SEMA4D inhibitor) and Trastuzumab (HER2 inhibitor) can significantly shrink tumors in animal model.

Of course, Merck must conduct a trial on the combination of SEMA4D inhibitor with Keytruda. I suppose Merck might acquire Vaccinex, which should happen before the publication of the results on the trial NCT05378464.

Adoptive T Cell Therapy Following HER2-Pulsed Dendritic Cell Vaccine & Pepinemab /?Trastuzumab in Patients w/? Metastatic HER2+ Breast Cancer
https://clinicaltrials.gov/study/NCT05378464

Pepinemab in Combination With Pembrolizumab in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (KEYNOTE-B84)
https://clinicaltrials.gov/study/NCT04815720

Clinical Collaboration Partner: Merck
https://vaccinex.com/partners/

Potentiating dendritic cell immunotherapy by interrupting the Semaphorin 4D-induced immune-suppressive barrier
https://cell.com/cell-reports/fulltext/S2211-1247(26)00128-2?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS2211124726001282%3Fshowall%3Dtrue

Combination therapy with semaphorin-4D blockade (SEMA4D) and DC1 therapy
https://patents.google.com/patent/EP3986446A1/en
8:36 PM · Apr 2, 2026
·
3,517
Views

$NWBO

April marks the primary completion of a DC1 vaccine trial (NCT05378464) conducted at Moffitt Cancer Center. The trial is about the following combination:

DC1 vaccine + Pepinemab(SEMA4D inhibitor) + Trastuzumab (HER2 inhibitor) + IL-15 Expanded HER2 specific CD4 Th1 cell +… pic.twitter.com/C5f9uQBmnx

— d_stock (@d_stock07734) April 2, 2026